Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy Life Science Investing
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy Life Science Investing
NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application Life Science Investing
NRx Pharmaceuticals Announces FDA Labeling Alignment for NRx's Preservative-Free Ketamine Application Life Science Investing
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 Life Science Investing
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 Life Science Investing
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 Life Science Investing
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 Life Science Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor Pharmaceutical Investing
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 Life Science Investing
